Lipoproteins in acute coronary syndromes--measure, treat or disregard?
Henkin
Yaakov
Y
Department of Cardiology, Soroka University Medical Center, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer Sheva, Israel. yaakovh@bgumail.bgu.ac.il
Goldbourt
Uri
U
Gottlieb
Shmuel
S
D003327:Coronary Disease / Q000097:blood* / Q000401:mortality / Q000517:prevention & control*; D016903:Drug Monitoring / Q000379:methods* / Q000592:standards; D019317:Evidence-Based Medicine; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D008074:Lipoproteins / Q000097:blood*; D017410:Practice Guidelines as Topic; D011322:Primary Prevention / Q000379:methods / Q000592:standards; D016896:Treatment Outcome
D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D008074:Lipoproteins